The following CME/CE courses are available for credit on ONA and myCME. Simply click on any link below to get started.
Shared Decision Making: Redefining the Therapeutic Landscape for Relapsed/Refractory Chronic Lymphocytic Leukemia
This two-hour enduring activity is a video capture of an educational symposium held in conjunction with the 2014 Pan Pacific Lymphoma Conference, which took place on July 21, 2014.
This activity offers:
2.00 / AMA PRA Category 1 CreditsTM
2.00 / CE for Nurses
A less common and more aggressive disease, IBC is unique in that it is a clinical diagnosis that relies on recognition of its signs and symptoms.
This review discusses common risk factors, treatment, and preventive measures for aspergillosis in hematopoietic stem transplantation recipients.
Oncology nurses must anticipate a disciplinary crossover between oncology and obstetrics to care for this unique subgroup of women with breast cancer.
Guidelines for managing chemotherapy-induced nausea and vomiting direct management toward risk assessment and prophylactic antiemetics.
Cancer cells hide from the body's natural defenses. This overview explains how immunotherapeutic strategies expose cancer cells to the immune system.
Head and neck cancer treatments have high morbidity rates. Newer options reduce morbidities and offer patients better quality of life after treatment.
The minimally invasive procedure provides effective, immediate relief from the pain of vertebral compression fractures due to multiple myeloma.
Advances in treatments, better risk assessment, and effective supportive care are leading to better outcomes for patients with lung cancer.
Understanding pain mechanisms and the types, triggers, and alleviating factors is needed to provide effective analgesia for patients with cancer.
This activity from myCME offers a review of groundbreaking molecular research and novel treatment options for patients with NSCLC.
Patients undergoing chemotherapy for hematologic cancers are at risk for this complication. The review can help you learn how to assess their risk.
A primer on what nurses need to know when scheduling items and services for patients participating in clinical trials.
Learn how patients' perceptions of health care can have a significant influence on the effectiveness of cancer care and patient education.
The CD20 antagonist is a potentially effective preventive and treatment for this common adverse effect of hematopoietic stem cell transplantation.
Signs and symptoms of venous thromboembolism in oncology patients should be heeded with prompt therapeutic and mechanical interventions.
This review describes the four major groups of leukemia, plus diagnostic tests and treatment regimens for each group.
Although the risks of erythropoietin-stimulating agents can outweigh the benefits, select patients may benefit.
VADs enable long-term IV therapy; however, the devices and their use pose a unique set of challenges for nurses.
CIPN is a debilitating adverse effect that can lead to reduced doses that hinder treatment effectiveness or early discontinuation of therapy.
Audiometric testing, awareness of the symptoms, and knowledge of which drugs are ototoxic can help protect young cancer patient's hearing.
- Harms of Cigarette Smoking and Health Benefits of Quitting (Fact Sheet)
- Clinical Trial Shows Vaccine Clears Some Precancerous Cervical Lesions
- Late-Stage Lung Cancer Often Overtreated
- Biomarker May Predict Prognosis for Targeted Therapy in Patients With HER2-Negative Breast Cancer
- "Supportive care" may hold less stigma than "palliative care"
- Testosterone Therapy Does Not Increase Aggressive Prostate Cancer Risk
- Laparascopic Surgery Does Not Improve Outcomes Over Open Resection for Rectal Cancer
- Bisphosphonates May Be Useful as Palliative Measure in Selected Patients
- Newly Identified Gene Mutations May Expand Indications for Existing Targeted Cancer Treatments
- Clinical Trial Populations May Not Represent Patients Using Studied Medications
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|